239 related articles for article (PubMed ID: 22466004)
1. Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood.
Lunnon K; Ibrahim Z; Proitsi P; Lourdusamy A; Newhouse S; Sattlecker M; Furney S; Saleem M; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Coppola G; Geschwind D; Simmons A; Lovestone S; Dobson R; Hodges A;
J Alzheimers Dis; 2012; 30(3):685-710. PubMed ID: 22466004
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease.
Lueg G; Gross CC; Lohmann H; Johnen A; Kemmling A; Deppe M; Groger J; Minnerup J; Wiendl H; Meuth SG; Duning T
Neurobiol Aging; 2015 Jan; 36(1):81-9. PubMed ID: 25277040
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial Alterations in Peripheral Mononuclear Blood Cells from Alzheimer's Disease and Mild Cognitive Impairment Patients.
Delbarba A; Abate G; Prandelli C; Marziano M; Buizza L; Arce Varas N; Novelli A; Cuetos F; Martinez C; Lanni C; Memo M; Uberti D
Oxid Med Cell Longev; 2016; 2016():5923938. PubMed ID: 26881032
[TBL] [Abstract][Full Text] [Related]
4. Increased apoptosis in the platelets of patients with Alzheimer's disease and amnestic mild cognitive impairment.
Zhao S; Zhao J; Zhang T; Guo C
Clin Neurol Neurosurg; 2016 Apr; 143():46-50. PubMed ID: 26895209
[TBL] [Abstract][Full Text] [Related]
5. Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk.
Leifert WR; Nguyen T; Rembach A; Martins R; Rainey-Smith S; Masters CL; Ames D; Rowe CC; Macaulay SL; François M; Fenech MF;
J Alzheimers Dis; 2015; 48(2):443-52. PubMed ID: 26402008
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
7. Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts.
Muenchhoff J; Poljak A; Song F; Raftery M; Brodaty H; Duncan M; McEvoy M; Attia J; Schofield PW; Sachdev PS
J Alzheimers Dis; 2015; 43(4):1355-73. PubMed ID: 25159666
[TBL] [Abstract][Full Text] [Related]
8. Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease.
Berchtold NC; Sabbagh MN; Beach TG; Kim RC; Cribbs DH; Cotman CW
Neurobiol Aging; 2014 Sep; 35(9):1961-72. PubMed ID: 24786631
[TBL] [Abstract][Full Text] [Related]
9. Lymphocytic mitochondrial aconitase activity is reduced in Alzheimer's disease and mild cognitive impairment.
Mangialasche F; Baglioni M; Cecchetti R; Kivipelto M; Ruggiero C; Piobbico D; Kussmaul L; Monastero R; Brancorsini S; Mecocci P
J Alzheimers Dis; 2015; 44(2):649-60. PubMed ID: 25322927
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial genes are altered in blood early in Alzheimer's disease.
Lunnon K; Keohane A; Pidsley R; Newhouse S; Riddoch-Contreras J; Thubron EB; Devall M; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Schalkwyk L; Dobson R; Malik AN; Powell J; Lovestone S; Hodges A;
Neurobiol Aging; 2017 May; 53():36-47. PubMed ID: 28208064
[TBL] [Abstract][Full Text] [Related]
11. Chromosomal DNA damage measured using the cytokinesis-block micronucleus cytome assay is significantly associated with cognitive impairment in South Australians.
Lee SL; Thomas P; Hecker J; Faunt J; Fenech M
Environ Mol Mutagen; 2015 Jan; 56(1):32-40. PubMed ID: 25099033
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease.
Oh J; Lee HJ; Song JH; Park SI; Kim H
Exp Gerontol; 2014 Dec; 60():87-91. PubMed ID: 25304332
[TBL] [Abstract][Full Text] [Related]
13. ADAM10 gene expression in the blood cells of Alzheimer's disease patients and mild cognitive impairment subjects.
Manzine PR; Marcello E; Borroni B; Kamphuis W; Hol E; Padovani A; Nascimento CC; de Godoy Bueno P; Assis Carvalho Vale F; Iost Pavarini SC; Di Luca M; Cominetti MR
Biomarkers; 2015; 20(3):196-201. PubMed ID: 26220620
[TBL] [Abstract][Full Text] [Related]
14. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
Ellis KA; Szoeke C; Bush AI; Darby D; Graham PL; Lautenschlager NT; Macaulay SL; Martins RN; Maruff P; Masters CL; McBride SJ; Pike KE; Rainey-Smith SR; Rembach A; Robertson J; Rowe CC; Savage G; Villemagne VL; Woodward M; Wilson W; Zhang P; Ames D;
Int Psychogeriatr; 2014 Apr; 26(4):543-54. PubMed ID: 24252258
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of interleukin-18 receptor in blood cells of subjects with mild cognitive impairment and Alzheimer's disease.
Salani F; Ciaramella A; Bizzoni F; Assogna F; Caltagirone C; Spalletta G; Bossù P
Cytokine; 2013 Feb; 61(2):360-3. PubMed ID: 23201485
[TBL] [Abstract][Full Text] [Related]
16. Prediction of mild cognitive impairment that evolves into Alzheimer's disease dementia within two years using a gene expression signature in blood: a pilot study.
Roed L; Grave G; Lindahl T; Rian E; Horndalsveen PO; Lannfelt L; Nilsson C; Swenson F; Lönneborg A; Sharma P; Sjögren M
J Alzheimers Dis; 2013; 35(3):611-21. PubMed ID: 23478308
[TBL] [Abstract][Full Text] [Related]
17. A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease.
Olazarán J; Gil-de-Gómez L; Rodríguez-Martín A; Valentí-Soler M; Frades-Payo B; Marín-Muñoz J; Antúnez C; Frank-García A; Acedo-Jiménez C; Morlán-Gracia L; Petidier-Torregrossa R; Guisasola MC; Bermejo-Pareja F; Sánchez-Ferro Á; Pérez-Martínez DA; Manzano-Palomo S; Farquhar R; Rábano A; Calero M
J Alzheimers Dis; 2015; 45(4):1157-73. PubMed ID: 25649659
[TBL] [Abstract][Full Text] [Related]
18. Lipidomic alterations in lipoproteins of patients with mild cognitive impairment and Alzheimer's disease by asymmetrical flow field-flow fractionation and nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry.
Kim SH; Yang JS; Lee JC; Lee JY; Lee JY; Kim E; Moon MH
J Chromatogr A; 2018 Sep; 1568():91-100. PubMed ID: 30007793
[TBL] [Abstract][Full Text] [Related]
19. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease.
Torres LL; Quaglio NB; de Souza GT; Garcia RT; Dati LM; Moreira WL; Loureiro AP; de Souza-Talarico JN; Smid J; Porto CS; Bottino CM; Nitrini R; Barros SB; Camarini R; Marcourakis T
J Alzheimers Dis; 2011; 26(1):59-68. PubMed ID: 21593563
[TBL] [Abstract][Full Text] [Related]
20. Leukocyte telomere length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's disease: a pilot study.
Movérare-Skrtic S; Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Zetterberg H; Blennow K; Svensson J
Exp Gerontol; 2012 Feb; 47(2):179-82. PubMed ID: 22210159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
